The effect of blood type of colorectal patients on long-term survival: a real-world study based on DACCA database_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

LIN Rongruo ^1,2 , ZHANG Ziwei ² , DU Yiling ² ,  WANG Xiaodong ^1,2 , LI Li ^1,2

1. Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
2. West China School of Medicine in Sichuan University, Chengdu 610041, P. R. China;

Corresponding author：

WANG Xiaodong, Email: wangxiaodong@wchscu.cn

Keywords：

colorectal cancer; blood type; pathological TNM staging; overall survival; disease specific survival

DOI：

10.7507/1007-9424.202209100

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objection To analyze the relationship between blood type and prognosis of colorectal cancer patients in the Database from Colorectal Cancer (DACCA). Methods The DACCA version selected for this data analysis was updated on January 5, 2022. The data items analysis included age, gender, blood type, tumor location, tumor pathological nature, pathological TNM (pTNM) stage, survival status and survival time. According to the ABO blood type classification, it was divided into four blood type groups: A blood type group, B blood type group, AB blood type group, and O blood type group. The overall survival (OS) and disease specific survival (DSS) were analyzed in four blood type groups, and the OS and DSS of each blood type group were analyzed in pTNM stage stratification. Results A total of3 486 rows of data were obtained from the DACCA database according to the screening conditions. There was no significantdifference in OS and DSS among blood typy A, B, AB and O group (P>0.05); At specific time points, the 1-year OS of the blood type A group was worse than that of blood type B (95.8% vs. 99.6%), the 1-year OS of the blood type B group was better than that of blood type O group (99.6% vs. 96.9%), and the differences were statistically significant (P<0.008 7), but the differences between OS and DSS in the remaining 1, 3, 5 and 10 years of patients with different blood type groups were not statistically significant (P>0.008 7). In each pTNM staging subgroup, the differences between 1, 3, 5 and 10-year OS and DSS were not statistically significant among different blood type groups (P>0.008 7). Conclusions Overall, there was no significant difference in prognosis among the blood type A, B, AB, and O groups. Comparing specific blood types and follow-up time, patients with blood type B have slightly better 1-year OS than patients with blood type A or blood type O. Comparisons between other ABO blood groups and between ABO blood groups classified by the pTNM staging subgroup did not show a difference.

Citation： LIN Rongruo, ZHANG Ziwei, DU Yiling, WANG Xiaodong, LI Li. The effect of blood type of colorectal patients on long-term survival: a real-world study based on DACCA database. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2022, 29(11): 1506-1513. doi: 10.7507/1007-9424.202209100 Copy

1.	Wei J, Zhang Y, Zheng J, et al. Prognostic value of ABO blood group in a Chinese population in Northwest China region with curatively resected rectal cancer. J Cancer, 2019, 10(26): 6584-6593.
2.	Cao X, Wen ZS, Sun YJ, et al. Prognostic value of ABO blood group in patients with surgically resected colon cancer. Br J Cancer, 2014, 111(1): 174-180.
3.	汪晓东, 刘健博, 李立. 数据库建设第五部分·结直肠癌的肿瘤特征—模块的设计 (二). 中国普外基础与临床杂志, 2020, 27(4): 483-488.
4.	汪晓东, 刘健博, 李立. 数据库建设第六部分: 结直肠癌分期的标签与结构化. 中国普外基础与临床杂志, 2020, 27(7): 873-879.
5.	汪晓东, 朱佳怡, 李立. 数据库建设第十一部分: 结直肠癌随访的标签与结构化. 中国普外基础与临床杂志, 2021, 28(10): 1353-1359.
6.	周嘉茗, 陈希, 林容若, 等. 结直肠癌患者年龄与住院流程的关系: 基于DACCA的真实世界数据研究. 中国普外基础与临床杂志, 2022, 29(8): 1073-1077.
7.	Zhang BL, He N, Huang YB, et al. ABO blood groups and risk of cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 2014, 15(11): 4643-4650.
8.	Urun Y, Ozdemir NY, Utkan G, et al. ABO and Rh blood groups and risk of colorectal adenocarcinoma. Asian Pac J Cancer Prev, 2012, 13(12): 6097-6100.
9.	Nakagoe T, Nanashima A, Sawai T, et al. Expression of blood group antigens A, B and H in carcinoma tissue correlates with a poor prognosis for colorectal cancer patients. J Cancer Res Clin Oncol, 2000, 126(7): 375-382.
10.	Luo Q, Pan M, Feng H, et al. ABO blood group antigen therapy: a potential new strategy against solid tumors. Sci Rep, 2021, 11(1): 16241.
11.	Le Pendu J, Marionneau S, Cailleau-Thomas A, et al. ABH and Lewis histo-blood group antigens in cancer. APMIS, 2001, 109(1): 9-31.
12.	Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet, 2014, 383(9927): 1490-1502.
13.	Zheng W, Lu Y, Feng X, et al. Improving the overall survival prognosis prediction accuracy: A 9-gene signature in CRC patients. Cancer Med, 2021, 10(17): 5998-6009.
14.	Ueno H, Mochizuki H, Akagi Y, et al. Optimal colorectal cancer staging criteria in TNM classification. J Clin Oncol, 2012, 30(13): 1519-1526.
15.	Bramsen JB, Rasmussen MH, Ongen H, et al. Molecular-subtype-specific biomarkers improve prediction of prognosis in colorectal cancer. Cell Rep, 2017, 19(6): 1268-1280.

1. Wei J, Zhang Y, Zheng J, et al. Prognostic value of ABO blood group in a Chinese population in Northwest China region with curatively resected rectal cancer. J Cancer, 2019, 10(26): 6584-6593.
2. Cao X, Wen ZS, Sun YJ, et al. Prognostic value of ABO blood group in patients with surgically resected colon cancer. Br J Cancer, 2014, 111(1): 174-180.
3. 汪晓东, 刘健博, 李立. 数据库建设第五部分·结直肠癌的肿瘤特征—模块的设计 (二). 中国普外基础与临床杂志, 2020, 27(4): 483-488.
4. 汪晓东, 刘健博, 李立. 数据库建设第六部分: 结直肠癌分期的标签与结构化. 中国普外基础与临床杂志, 2020, 27(7): 873-879.
5. 汪晓东, 朱佳怡, 李立. 数据库建设第十一部分: 结直肠癌随访的标签与结构化. 中国普外基础与临床杂志, 2021, 28(10): 1353-1359.
6. 周嘉茗, 陈希, 林容若, 等. 结直肠癌患者年龄与住院流程的关系: 基于DACCA的真实世界数据研究. 中国普外基础与临床杂志, 2022, 29(8): 1073-1077.
7. Zhang BL, He N, Huang YB, et al. ABO blood groups and risk of cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 2014, 15(11): 4643-4650.
8. Urun Y, Ozdemir NY, Utkan G, et al. ABO and Rh blood groups and risk of colorectal adenocarcinoma. Asian Pac J Cancer Prev, 2012, 13(12): 6097-6100.
9. Nakagoe T, Nanashima A, Sawai T, et al. Expression of blood group antigens A, B and H in carcinoma tissue correlates with a poor prognosis for colorectal cancer patients. J Cancer Res Clin Oncol, 2000, 126(7): 375-382.
10. Luo Q, Pan M, Feng H, et al. ABO blood group antigen therapy: a potential new strategy against solid tumors. Sci Rep, 2021, 11(1): 16241.
11. Le Pendu J, Marionneau S, Cailleau-Thomas A, et al. ABH and Lewis histo-blood group antigens in cancer. APMIS, 2001, 109(1): 9-31.
12. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet, 2014, 383(9927): 1490-1502.
13. Zheng W, Lu Y, Feng X, et al. Improving the overall survival prognosis prediction accuracy: A 9-gene signature in CRC patients. Cancer Med, 2021, 10(17): 5998-6009.
14. Ueno H, Mochizuki H, Akagi Y, et al. Optimal colorectal cancer staging criteria in TNM classification. J Clin Oncol, 2012, 30(13): 1519-1526.
15. Bramsen JB, Rasmussen MH, Ongen H, et al. Molecular-subtype-specific biomarkers improve prediction of prognosis in colorectal cancer. Cell Rep, 2017, 19(6): 1268-1280.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

The effect of blood type of colorectal patients on long-term survival: a real-world study based on DACCA database

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content